In addition, there were statistically significant differences at both time points on reduction on in symptom severity (IBS-SSS) and adequate relief (IBS-AR), and a trend toward significance at the 21-day endpoint on improvement in quality of life (IBS-QOL).
← all excerpts
Placebos without deception: a randomized controlled trial in irritable bowel syndrome.
1
—
—